Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?

被引：5

作者：

Castellino, G. ^{[1
]}

Corallini, F. ^{[2
]}

Trotta, F. ^{[1
]}

Secchiero, P. ^{[2
]}

机构：

[1] Univ Ferrara, Dept Clin & Expt Med, Rheumatol Sect, I-44100 Ferrara, Italy

[2] Univ Ferrara, Dept Morphol & Embryol, Human Anat Sect, I-44100 Ferrara, Italy

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2008年 / 67卷 / 08期

关键词：

D O I：

10.1136/ard.2007.081067

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1196 / 1197

页数：2

共 10 条

[1] Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists [J].

Gonzalez-Alvaro, Isidoro ;

Ortiz, Ana M. ;

Tomero, Eva G. ;

Balsa, Alejandro ;

Orte, Javier ;

Laffon, Armando ;

Garcia-Vicuna, Rosario .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (12) :1675-1678

[2] Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand [J].

Lee, CK ;

Lee, EY ;

Chung, SM ;

Mun, SH ;

Yoo, B ;

Moon, HB .

ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :3831-3843

[3] Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells [J].

Miyashita, T ;

Kawakami, A ;

Nakashima, T ;

Yamasaki, S ;

Tamai, M ;

Tanaka, F ;

Kamachi, M ;

Ida, H ;

Migita, K ;

Origuchi, T ;

Nakao, K ;

Eguchi, K .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 137 (02) :430-436

[4]

QINGPING Y, 2006, ARTHRITIS RES THER, V8, pR16

[5] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression [J].

Song, KM ;

Chen, YG ;

Göke, R ;

Wilmen, A ;

Seidel, C ;

Göke, A ;

Hilliard, B ;

Chen, YH .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07) :1095-1103

[6] Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis [J].

Vis, M. ;

Havaardsholm, E. A. ;

Haugeberg, G. ;

Uhlig, T. ;

Voskuyl, A. E. ;

van de Stadt, R. J. ;

Dijkmans, B. A. C. ;

Woolf, A. D. ;

Kvien, T. K. ;

Lems, W. F. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (11) :1495-1499

[7] TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF [J].

Zauli, G ;

Rimondi, E ;

Nicolin, V ;

Melloni, E ;

Celeghini, C ;

Secchiero, P .

BLOOD, 2004, 104 (07) :2044-2050

[8] TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors [J].

Zauli, Giorgio ;

Rimond, Erika ;

Stea, Susanna ;

Baruffaldi, Fabio ;

Stebel, Marco ;

Zerbinati, Carlotta ;

Corallini, Federica ;

Secchiero, Paola .

JOURNAL OF CELLULAR PHYSIOLOGY, 2008, 214 (01) :117-125

[9] The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology [J].

Zauli, Giorgio ;

Secchiero, Paola .

CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (04) :245-257

[10] High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment [J].

Ziolkowska, M ;

Kurowska, M ;

Radzikowska, A ;

Luszczykiewicz, G ;

Wiland, P ;

Dziewczopolski, W ;

Filipowicz-Sosnowska, A ;

Pazdur, J ;

Szechinski, J ;

Kowalczewski, J ;

Rell-Bakalarska, M ;

Maslinski, W .

ARTHRITIS AND RHEUMATISM, 2002, 46 (07) :1744-1753

← 1 →